Sutro Biopharma (STRO) Current Assets (2017 - 2026)

Sutro Biopharma has reported Current Assets for 9 years, with the latest figure at $150.9 million in Q4 2025.

• Quarterly Current Assets fell 56.04% year-over-year to $150.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $150.9 million (down 56.04% YoY) and the FY2025 annual result came in at $150.9 million, down 56.04% from the prior year.
• Current Assets retreated to $150.9 million in Q4 2025 per STRO's latest filing, from $182.1 million in the prior quarter.
• Over five years, Current Assets peaked at $443.5 million in Q2 2024 and troughed at $150.9 million in Q4 2025.
• A 5-year average of $309.5 million and a median of $317.8 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2021 and 2025: Current Assets soared 108.7% in 2021, then plunged 56.04% in 2025.
• Over 5 years, Current Assets stood at $218.5 million in 2021, then surged by 61.61% to $353.2 million in 2022, then increased by 19.37% to $421.5 million in 2023, then slipped by 18.56% to $343.3 million in 2024, then plunged by 56.04% to $150.9 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $150.9 million, $182.1 million, and $231.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.